Conexeu Sciences Adds Three Fortune 500 Directors, Boosts Board to Nine
ESTA•Conexeu Sciences expanded its board from six to nine directors, adding Ana Bastiani-Posner, April Burke and Andrew Costa for healthcare finance, capital markets and growth-equity expertise. Co-founder David Bogart was named Chief Commercial Officer and Melinda Farina joined the advisory board to drive aesthetics market entry.
1. Board Expansion and Strategic Hires
On June 15, 2026, Conexeu Sciences increased its board from six to nine members, appointing Ana Bastiani-Posner (Kyowa Kirin North America CFO), April Burke (Lucid Hearing CFO) and Andrew Costa (RX3 Growth Partners Co-Managing Partner) to strengthen finance, M&A and capital markets governance.
2. Executive Promotion and Advisory Addition
Co-founder David Bogart was elevated to Chief Commercial Officer to lead go-to-market strategy and operations, leveraging his $75 million capital-formation track record, while aesthetics consultant Melinda Farina joined the advisory board to guide consumer-health branding and market positioning.
3. Commercialization Focus and Regulatory Timeline
Conexeu’s preclinical CXU™ extracellular matrix platform underpins its Ten-Minute Tissue™ device, with the company targeting an early-2027 FDA 510(k) submission as it shifts from research into commercialization and pursues entry into regenerative and aesthetic medicine markets.
